Alemtuzumab - Bayer/Sanofi

Next Previous
Drug Profile

Alemtuzumab - Bayer/Sanofi

Alternative Names: Anti-CD52 monoclonal antibody; Campath; Campath-1H; LDP-03; Lemtrada; MabCampath; MabKampat; Remniq

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Cambridge
  • Developer Bayer HealthCare Pharmaceuticals Inc.; Dana-Farber Cancer Institute; German CLL Study Group; Ohio State University Comprehensive Cancer Center; Sanofi; Sanofi Oncology; University of Cologne
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD52 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Multiple sclerosis
  • Phase II T cell prolymphocytic leukaemia
  • Phase I Lymphoma
  • No development reported Diffuse large B cell lymphoma; Graft-versus-host disease; T cell lymphoma
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 13 Dec 2017 Sanofi plans a pivotal phase III trial for Multiple sclerosis (primary progressive) in 2018
  • 28 Nov 2017 No recent reports of development identified for phase-I development in Diffuse large B cell lymphoma(Combination therapy, First-line therapy) in USA (SC)
  • 28 Nov 2017 No recent reports of development identified for phase-I development in T-cell-lymphoma(Combination therapy, First-line therapy) in USA (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top